Ribociclib with radiation for high-risk HR+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether adding the targeted therapy ribociclib (Kisqali) to radiation after surgery reduces the risk of breast cancer returning in patients with high-risk, hormone-positive breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be hormone receptor-positive (ER and/or PR ≥1%) and HER2-negative.
- You must have high-risk features, like more than 3 positive lymph nodes, or 1-3 positive nodes with a large tumor or high-grade cancer.
- You need to have had all visible breast cancer surgically removed (negative margins) at least 21 days before starting the trial.
- You must have completed chemotherapy (before or after surgery) and recovered from most side effects.
- You must not have had prior radiation to the chest or armpit nodes, or ever taken a CDK4/6 inhibitor (like Ibrance, Kisqali, or Verzenio).
- Your cancer must not have spread beyond the lymph nodes to other organs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.